Aratana Therapeutics Inc. (Nasdaq: PETX) reported positive results from a
field effectiveness study of the appetite stimulation drug capromorelin
for dogs. The stock price climbed $1.41 to close at $14.85.
Positive study results for Aratana Therapeutics
June 29, 2015 at 16:55 PM EDT
